{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:48:46Z","timestamp":1761857326858,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.medcli.2022.04.003","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:40:07Z","timestamp":1655772007000},"page":"336-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Aminobisfosfonatos: reconsideraci\u00f3n a los 25 a\u00f1os de su aprobaci\u00f3n para el tratamiento de la osteoporosis"],"prefix":"10.1016","volume":"159","author":[{"given":"Jes\u00fas","family":"Gonz\u00e1lez Mac\u00edas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Olmos Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2022.04.003_bib0305","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00223-004-0024-1","article-title":"From molds and macrophages to mevalonate: A decade of progress in understanding the molecular mode of action of bisphosphonates","volume":"75","author":"Rogers","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.medcli.2022.04.003_bib0310","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1185\/030079904125004475","article-title":"Bone safety of long-term bisphosphonate treatment","volume":"20","author":"Rodan","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.medcli.2022.04.003_bib0315","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1021\/jm7015733","article-title":"Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: Time-dependent inhibition of human farnesyl pyrophosphate synthase","volume":"51","author":"Duford","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.medcli.2022.04.003_bib0320","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.medcli.2022.04.003_bib0325","doi-asserted-by":"crossref","first-page":"116289","DOI":"10.1016\/j.bone.2021.116289","article-title":"Bisphosphonates:The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use","volume":"156","author":"Ebetino","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.medcli.2022.04.003_bib0330","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1742-1241.2008.01704.x","article-title":"A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International","volume":"62","author":"Reid","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.medcli.2022.04.003_bib0335","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: A randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2022.04.003_bib0340","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1359\/jbmr.091009","article-title":"Fluorescent risedronate analogs reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo","volume":"25","author":"Roelofs","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2022.04.003_bib0345","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1359\/jbmr.080617","article-title":"Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo","volume":"23","author":"Plotkin","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2022.04.003_bib0350","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/00325481.2017.1362312","article-title":"Osteoblast as a target of antiosteoporotic treatment","volume":"129","author":"Corrado","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.medcli.2022.04.003_bib0355","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2022.04.003_bib0360","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jbmr.4178","article-title":"Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of antiresorptive drugs: Proportion of treatment effect explained","volume":"36","author":"Eastell","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2022.04.003_bib0365","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2022.04.003_bib0370","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2022.04.003_bib0375","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2022.04.003_bib0380","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2022.04.003_bib0385","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2022.04.003_bib0390","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2022.04.003_bib0395","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2022.04.003_bib0400","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/TCRM.S52291","article-title":"Eliminating the need for fasting with oral administration of bisphosphonates","volume":"9","author":"Pazianas","year":"2013","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.medcli.2022.04.003_bib0405","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Oral ibandronate osteoporosis vertebral fracture trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2022.04.003_bib0410","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2022.04.003_bib0415","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2022.04.003_bib0420","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Eng J Med"},{"key":"10.1016\/j.medcli.2022.04.003_bib0425","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2022.04.003_bib0430","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2022.04.003_bib0435","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: A network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2022.04.003_bib0440","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bone.2016.05.013","article-title":"Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis","volume":"89","author":"Sanderson","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.medcli.2022.04.003_bib0445","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1302\/2046-3758.67.BJR-2016-0292.R1","article-title":"The efficacy and safety of vertebral fracture prevention therapies in postmenopausal osteoporosis treatment","volume":"6","author":"Wang","year":"2017","journal-title":"Bone Joint Res"},{"key":"10.1016\/j.medcli.2022.04.003_bib0450","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/GME.0000000000001321","article-title":"Comparative efficacy and safety of pharmacological interventions fior osteoporosis in postmenopausal women: A network meta-analysis (Chongqing, China)","volume":"26","author":"Tan","year":"2019","journal-title":"Menopause"},{"key":"10.1016\/j.medcli.2022.04.003_bib0455","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00198-006-0274-z","article-title":"Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study","volume":"18","author":"Silverman","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2022.04.003_bib0460","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00198-008-0772-2","article-title":"RisedronatE and ALendronate Intervention over Three Years (REALITY): Minimal differences in fracture risk reduction","volume":"20","author":"Curtis","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2022.04.003_bib0465","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00198-021-06108-w","article-title":"Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: A claims data analysis","volume":"33","author":"Thomasius","year":"2022","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2022.04.003_bib0470","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2022.04.003_bib0475","doi-asserted-by":"crossref","first-page":"e0196419","DOI":"10.1371\/journal.pone.0196419","article-title":"The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects","volume":"13","author":"Chiu","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.medcli.2022.04.003_bib0480","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3390\/antiox10050680","article-title":"Various therapeutic methods for the treatment of medication-related osteonecrosis of the jaw (MRONJ) and their limitations: A narrative review on new molecular and cellular therapeutic approaches","volume":"10","author":"On","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.medcli.2022.04.003_bib0485","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jbmr.3860","article-title":"Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women","volume":"35","author":"Reid","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2022.04.003_bib0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-015-3334-4","article-title":"Treatment of osteoporosis after alendronate or risedronate","volume":"27","author":"Eiken","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2022.04.003_bib0495","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: The VERO trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2022.04.003_bib0500","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2022.04.003_bib0505","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.medcli.2022.04.003_bib0510","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2022.04.003_bib0515","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2022.04.003_bib0520","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2022.04.003_bib0525","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2022.04.003_bib0530","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2022.04.003_bib0535","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: Differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2022.04.003_bib0540","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2022.04.003_bib0545","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2022.04.003_bib0550","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2022.04.003_bib0555","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2022.04.003_bib0560","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2022.04.003_bib0565","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: Meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.medcli.2022.04.003_bib0570","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: A randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2022.04.003_bib0575","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00198-008-0604-4","article-title":"Risk of hip fracture after bisphosphonate discontinuation: Implications for a drug holiday","volume":"19","author":"Curtis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2022.04.003_bib0580","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1007\/s00198-017-4215-9","article-title":"Bisphosphonate drug holidays in postmenopausal osteoporosis: Effect on clinical fracture risk","volume":"28","author":"Mignot","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2022.04.003_bib0585","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/jbmr.3420","article-title":"Bisphosphonate drug holiday and fracture risk: A population-based cohort study","volume":"33","author":"Adams","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2022.04.003_bib0590","doi-asserted-by":"crossref","first-page":"115431","DOI":"10.1016\/j.bone.2020.115431","article-title":"Bisphosphonate drug holidays: Risk of fractures and mortality in a prospective cohort study","volume":"138","author":"Pfeilschifter","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.medcli.2022.04.003_bib0595","doi-asserted-by":"crossref","unstructured":"Riancho JA, Peris P, Gonz\u00e1lez-Mac\u00edas G, P\u00e9rez-Castrill\u00f3n JL, en nombre de la Comisi\u00f3n de Redacci\u00f3n de las Gu\u00edas de Osteoporosis de la SEIOMM. Resumen ejecutivo de las gu\u00edas de pr\u00e1ctica cl\u00ednica en la osteoporosis posmenop\u00e1usica, glucocorticoidea y del var\u00f3n (actualizaci\u00f3n 2022). Sociedad Espa\u00f1ola de Investigaci\u00f3n \u00d3sea y del Metabolismo Mineral (SEIOMM). Disponible online.https:\/\/doi.org\/10.1016\/j.rce.2021.12.007","DOI":"10.1016\/j.rce.2021.12.007"},{"key":"10.1016\/j.medcli.2022.04.003_bib0600","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Eng J Med"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775322001804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775322001804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:55:19Z","timestamp":1758419719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775322001804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0025775322001804"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2022.04.003","relation":{},"ISSN":["0025-7753"],"issn-type":[{"type":"print","value":"0025-7753"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aminobisfosfonatos: reconsideraci\u00f3n a los 25 a\u00f1os de su aprobaci\u00f3n para el tratamiento de la osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2022.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}